Insulet Corporation
Case Overview
55 Days Left to Seek Lead Plaintiff
| Lead Plaintiff Deadline: | Lead Plaintiff Deadline: 08/31/2026 |
| Status: | Status: Investigating |
| Company Name: | Company Name: Insulet Corporation |
| Court: | Court: District of Massachusetts |
| Case Number: | Case Number: 1:26cv13062 |
| Class Period: | Class Period: 02/21/2025 - 05/26/2026 |
| Ticker: | Ticker: PODD |
| Related Attorneys: | Lead Attorneys: Thomas W. Elrod |
| Related Practices: | Related Practices: Securities |
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Insulet Corporation (“Insulet” or the “Company”) (NASDAQ:PODD) securities during the period of February 21, 2025 through May 26, 2026, inclusive (“the Class Period”).
The lawsuit alleges that throughout the Class Period, Insulet made public statements that were misleading for failure to disclose that: (i) Insulet’s manufacturing controls and procedures were defective and (ii) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury.
On March 12, 2026, Insulet disclosed that it had “initiated a voluntary Medical Device Correction for specific lots of Omnipod 5 Pods after identifying a manufacturing issue through its ongoing product monitoring.” On this news, the price of Insulet shares declined by $16.23 per share, or approximately 7%, from $236.07 per share on March 12, 2026 to close at $219.84 on March 13, 2026.
Then, on May 26, 2026, Insulet disclosed the “initiation” of another “voluntary Medical Device Correction”, this time “for specific lots of Omnipod 5, Omnipod Dash, and Omnipod Insulin Management System (Omnipod Eros) Pods due to a manufacturing issue, identified through ongoing product monitoring, that could result in insulin under-delivery.” On this news, the price of Insulet shares declined by $7.79 per share, or approximately 5%, from $153.80 per share on May 26, 2026 to close at $146.01 on May 27, 2026.
The lawsuit alleges that throughout the Class Period, Insulet made public statements that were misleading for failure to disclose that: (i) Insulet’s manufacturing controls and procedures were defective and (ii) the foregoing created a foreseeable heightened risk that one or more Insulet products would be found to be in violation of applicable safety regulations and/or pose a risk of injury.
On March 12, 2026, Insulet disclosed that it had “initiated a voluntary Medical Device Correction for specific lots of Omnipod 5 Pods after identifying a manufacturing issue through its ongoing product monitoring.” On this news, the price of Insulet shares declined by $16.23 per share, or approximately 7%, from $236.07 per share on March 12, 2026 to close at $219.84 on March 13, 2026.
Then, on May 26, 2026, Insulet disclosed the “initiation” of another “voluntary Medical Device Correction”, this time “for specific lots of Omnipod 5, Omnipod Dash, and Omnipod Insulin Management System (Omnipod Eros) Pods due to a manufacturing issue, identified through ongoing product monitoring, that could result in insulin under-delivery.” On this news, the price of Insulet shares declined by $7.79 per share, or approximately 5%, from $153.80 per share on May 26, 2026 to close at $146.01 on May 27, 2026.